MedTrace Logo

Oxaliplatin - Induced Peripheral Neuropathy in Patients With Gastrointestinal Tract Cancer

NCT02428101 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2023-11-28

No results posted yet for this study

Summary

This study will examine DNA from Gastrointestinal Tract of cancer patients treated with oxaliplatin to look for a variation (mutation) of the ABCG2 gene that may lead to drug-induced peripheral neuropathy in certain patients.

The DNA will be extracted from patients' blood samples and are analyzed for the ABCG2 single nucleotide polymorphism (G34A - rs2231137 and A/A -rs3114018 genotypes) and correlated with peripheral neuropathy grades.

Conditions

Interventions

GENETIC

polymorphism analysis

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Inas M Moukhtar Ahmed, B.pharma · Faculty of Pharmacy, Ain Shams Universty

  • Lamia M El Wakeel, Assoc. Prof · Clinical Pharmacy, Ain Shams University

  • Abdel Hady A Abdel Wahab, Professor · Biochemistry & Molecular biology,Cairo University

  • Amr S Saad, Assoc. Prof · Clinical Oncology, Ain Shams University

  • Raafat R Abdel-Malek, Assoc. Prof · clinical oncology, cairo university

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2024-02-29
Completion
2024-04-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02428101 on ClinicalTrials.gov